Inspire Medical Systems, Inc. to Present at the KeyBanc Capital Markets Healthcare Forum
Rhea-AI Summary
Inspire Medical Systems (NYSE: INSP) announced its management will present at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026 at 1:30 p.m. ET. The presentation will be available via live webcast and a replay will be posted for two weeks in the Event Archive.
Investors can access the live webcast and the two-week replay on Inspire’s investor website Event Archive at the provided URL.
Positive
- None.
Negative
- None.
News Market Reaction – INSP
On the day this news was published, INSP gained 1.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INSP gained 0.47% while key medical device peers like ATEC, HAE, PRCT, QDEL, and LIVN also showed positive moves, but no peers appeared in the momentum scanner, suggesting today’s move is more stock-specific than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings results | Positive | -12.6% | Reported strong 4Q25 and FY25 financial results and updated 2026 guidance. |
| Jan 12 | Prelim revenue | Positive | -1.5% | Issued preliminary Q4 and FY25 revenue and initial 2026 revenue guidance. |
| Jan 07 | Earnings date set | Neutral | +1.9% | Announced date and time for 4Q25 and FY25 financial results call. |
| Dec 29 | Conference presentation | Neutral | -1.9% | Disclosed presentation plans for the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 18 | Conference presentation | Neutral | -1.5% | Announced participation in the Piper Sandler 37th Annual Healthcare Conference. |
Recent history shows positive earnings-related news followed by negative price reactions, while conference and presentation announcements have been associated with relatively modest moves.
Over the last few months, INSP reported strong 4Q25 and FY25 results on Feb 11, 2026, including higher revenue and EPS, yet the stock fell 12.55%. Preliminary unaudited revenue and upbeat 2026 guidance on Jan 12, 2026 also saw a 1.47% decline. By contrast, announcements about upcoming earnings dates and presentations at major conferences like J.P. Morgan and Piper Sandler led to smaller, mixed price reactions, framing today’s KeyBanc forum appearance as part of an ongoing investor outreach cadence.
Market Pulse Summary
This announcement adds another investor-relations touchpoint, with management presenting at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026 at 1:30 p.m. Eastern Time. It follows a series of conference appearances and recent earnings updates, including notable price reactions around the Feb 11, 2026 results. Investors may focus on any new commentary around growth drivers, reimbursement dynamics, and recent operational trends, with the two-week webcast replay offering additional opportunity to review management’s messaging.
Key Terms
obstructive sleep apnea medical
webcast technical
AI-generated analysis. Not financial advice.
MINNEAPOLIS, March 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026.
Inspire is scheduled to present at 1:30 p.m. Eastern Time. The presentation will be accessible via a live webcast here.
A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443